CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 80.96% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.
Open platformOpen platform

ImmuCell Q3 revenue surges; swings to profit

By Reuters News


Overview

  • Animal health biologics firm's Q3 revenue rose 46% yr/yr, aided by distributor restocking timing

  • Q3 net income swung to profit from year-ago loss


Outlook

  • Company investing in capacity expansion and colostrum sourcing to meet future demand

  • Company expects to sign new $3 mln line of credit in Q4 2026

  • Company sees favorable inventory levels heading into peak season


Result Drivers

  • DISTRIBUTOR RESTOCKING - Revenue growth benefited from the absence of distributor restocking headwinds that had hurt Q3 2025 sales

  • VOLUME AND SALES ACTIVITY - Co said distributor out-the-door volume grew 18% yr/yr, with broad-based growth across sales territories and product lines supported by increased sales activity and customer acquisition

  • HIGHER PRICING AND MANUFACTURING EXECUTION - Gross margin rose due to higher pricing and improved manufacturing execution, partially offset by shift of some product development expenses to cost of goods sold


Company press release:


Key Details

Metric

Beat/Miss

Actual

Consensus Estimate

Q3 Product Sales

$8.04 mln

Q3 EPS

$0.10

Q3 Net Income

$953,000

Q3 Basic EPS

$0.10

Q3 Operating Expenses

$2.60 mln

Q3 Pretax Profit

$936,000


Reuters Recommended Reads

  • Nov 10 - Scholar Rock posts first product revenue after ISEMBYLD launch

  • Nov 12 - Fennec Pharma Q3 product sales rise 56% on PEDMARK demand

  • Nov 12 - Pelthos Q3 Zelsuvmi revenue jumps 114%, net loss narrows


For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.


(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.

The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.

To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.

Any information which could be construed as “investment research” has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such is considered to be a marketing communication.